BioAsia 2012 truly leveraged the ninth edition's theme of "Optimizing Opportunities" in a well-coordinated, dynamic global forum. The most happening lifesciences segments - Vaccines and Contract Research - found an added impetus through valuable inputs, discussions, interactions and perspectives by industry thought leaders and key stakeholders.
This year, BioAsia is geared to carry forward the momentum with its tenth edition - BioAsia 2013, from 28th to 30th January 2013 at HICC, Hyderabad, India. You can expect the best convergence at this much-awaited and most comprehensive llfesciences dynamic global forum.
This time, through the succinct, cutting-edge theme of TECHNOLGIES.BUSINESS.NEXT, BioAsia 2013 will explore a bio-future waiting to be shaped by the NEXT big industry trends: Biologics & Biosimilars.
The advancements in Biologics are not just rapidly realigning perceptions regarding medical
concepts but also opening up a land mine of opportunities in the area of Bio-Pharmaceutical drugs. On one
hand is the clear advantage that Bio-pharmaceutical drugs can address - the hitherto unmanageable clinical
needs by conventional therapeutics and therefore worth a premium.
Read More
Parallel to Biologics, another trend is the rapidly growing interest in Biosimilars. This is clearly fueled
by the expiry of patents due on at least 48 biologics with a combined global market size of nearly $ 73 billion
across the globe over the next decade. There is an increasing demand for low-cost medicines from healthcare
players around the world as they struggle to contain soaring healthcare
Read More
Lower R&D costs, strategic plans for clinical trials, future commercialization with companies in the
US and EUROPE, a solid foundation in scientific intellectual capital and technical framework ensuring
world class quality standards have already given the Indian pharmaceutical companies a head start over
their global counterparts.
Read More
